HiTS Seminar: Keith Flaherty, MD, 10:00 am, Thursday, May 16, 2019
Director of Clinical Research, Massachusetts General Hospital
Professor of Medicine, Harvard Medical School
Determinants of response and resistance to targeted therapies and immunotherapy in melanoma
Significant therapeutic advances have been made in advanced melanoma over the past decade. For almost half of melanoma patients, BRAF inhibitor-based therapy has provided a reliable disease-controlling therapy in the metastatic setting and curative effect in the adjuvant setting. For those same patients and the remaining population of melanoma patients whose tumor lack a BRAF mutation, immune checkpoint antibody therapy has produced a benefit that was first documented in melanoma prior to extending to 14 additional cancer types. Ongoing research continues to focus on resistance to both therapeutic types in model systems and in patients’ tumors. An emerging theme has been the elucidation of a epigenetic state change that associates with resistance to both BRAF inhibitor and immune checkpoint antibody-based therapy. This evidence and emerging evidence supporting therapeutic approaches that might undercut the determinants of resistance will be discussed.
10:00 am – 11:00 am
Thursday, May 16, 2019
Harvard Medical School
200 Longwood Avenue
Warren Alpert Bldg, Room 563
Boston, MA 02115
Hosted by Luca Gerosa, Ph.D.